{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:45:54Z","timestamp":1787849154660,"version":"build-2784847793"},"reference-count":48,"publisher":"Siapec Servizi Srl","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1603","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:31:08Z","timestamp":1775737868000},"page":"571-579","source":"Crossref","is-referenced-by-count":1,"title":["PIK3CA testing in HR+\/HER2\u2212 metastatic breast cancer: assessing pathology laboratories capacity and needs"],"prefix":"10.32074","volume":"117","author":[{"given":"Eltjona","family":"Mane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PIK3CA in breast cancer GIPaM\/PMMP cooperative group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Frascarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariantonia","family":"Nacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pisapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"De Camilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Costarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Scatena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Guerini-Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"10.32074\/1591-951X-1603_ref1","doi-asserted-by":"crossref","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021;32(12):1475-95.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"10.32074\/1591-951X-1603_ref2","unstructured":"Sukhun SA, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, et al. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource\u2013Stratified Guideline. JCO Global Oncology. 2024(10):e2300285."},{"key":"10.32074\/1591-951X-1603_ref3","unstructured":"Curigliano G, Castelo-Branco L, Gennari A, Harback N, Criscitiello C, Trapani D. ESMO metastatic breast cancer living guideline v1.1 May 2023 [Original citation]. Ann Oncol. 2023;32(12):1475-95."},{"key":"10.32074\/1591-951X-1603_ref4","unstructured":"Senkus E, Delaloge S, Domchek SM, Conte P, Im SA, Xu B, et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer. 2023."},{"key":"10.32074\/1591-951X-1603_ref5","doi-asserted-by":"crossref","unstructured":"Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, et al. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast cancer research and treatment. 2020;184(2):265-75.","DOI":"10.1007\/s10549-020-05849-2"},{"key":"10.32074\/1591-951X-1603_ref6","unstructured":"Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, et al. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2022;0(0):JCO.22.01063."},{"key":"10.32074\/1591-951X-1603_ref7","doi-asserted-by":"crossref","unstructured":"Bardia A, Cort\u00e9s J, Bidard FC, Neven P, Garcia-S\u00e1enz J, Aftimos P, et al. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4\/6 Inhibitor and in Clinical Subgroups. Clin Cancer Res. 2024;30(19):4299-309.","DOI":"10.1158\/1078-0432.CCR-24-1073"},{"key":"10.32074\/1591-951X-1603_ref8","doi-asserted-by":"crossref","unstructured":"Fusco N, Malapelle U. Next-generation sequencing for PTEN testing in HR+\/HER2- metastatic breast cancer. Crit Rev Oncol Hematol. 2025:104626.","DOI":"10.1016\/j.critrevonc.2025.104626"},{"key":"10.32074\/1591-951X-1603_ref9","doi-asserted-by":"crossref","unstructured":"Zeng Z, Yi Z, Xu B. The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients. Cancer Lett. 2025;616:217574.","DOI":"10.1016\/j.canlet.2025.217574"},{"key":"10.32074\/1591-951X-1603_ref10","doi-asserted-by":"crossref","unstructured":"Guerini-Rocco E, Venetis K, Cursano G, Mane E, Frascarelli C, Pepe F, et al. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+\/HER2- metastatic breast cancer. Crit Rev Oncol Hematol. 2024;201:104427.","DOI":"10.1016\/j.critrevonc.2024.104427"},{"key":"10.32074\/1591-951X-1603_ref11","doi-asserted-by":"crossref","unstructured":"Varga Z, Maccio U. Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools. Virchows Arch. 2024;484(2):247-61.","DOI":"10.1007\/s00428-023-03709-0"},{"key":"10.32074\/1591-951X-1603_ref12","doi-asserted-by":"crossref","unstructured":"Boscolo Bielo L, Guerini Rocco E, Crimini E, Repetto M, Lombardi M, Zanzottera C, et al. Molecular tumor board in patients with metastatic breast cancer. Breast cancer research and treatment. 2025;210(1):45-55.","DOI":"10.1007\/s10549-024-07535-z"},{"key":"10.32074\/1591-951X-1603_ref13","doi-asserted-by":"crossref","unstructured":"Aristei C, Tomatis M, Antonio P, Marotti L, Cardoso MJ, Cheung KL, et al. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network. Eur J Cancer. 2024;196:113438.","DOI":"10.1016\/j.ejca.2023.113438"},{"key":"10.32074\/1591-951X-1603_ref14","doi-asserted-by":"crossref","unstructured":"Weiss A, Lopez NE, Ward EP, Lee KC, Caudle AS, Dickson-Witmer D, et al. Challenges in Clinical Trial Implementation: Results from a Survey of the National Accreditation Program of Breast Centers (NAPBC). Annals of surgical oncology. 2019;26(13):4364-71.","DOI":"10.1245\/s10434-019-07807-9"},{"key":"10.32074\/1591-951X-1603_ref15","doi-asserted-by":"crossref","unstructured":"Fusco N, Malapelle U, Fassan M, Marchio C, Buglioni S, Zupo S, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Front Oncol. 2021;11:644737.","DOI":"10.3389\/fonc.2021.644737"},{"key":"10.32074\/1591-951X-1603_ref16","doi-asserted-by":"crossref","unstructured":"Markham A. Alpelisib: First Global Approval. Drugs. 2019;79(11):1249-53.","DOI":"10.1007\/s40265-019-01161-6"},{"key":"10.32074\/1591-951X-1603_ref17","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer. New England Journal of Medicine. 2019;380(20):1929-40.","DOI":"10.1056\/NEJMoa1813904"},{"key":"10.32074\/1591-951X-1603_ref18","doi-asserted-by":"crossref","unstructured":"Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132:102861.","DOI":"10.1016\/j.ctrv.2024.102861"},{"key":"10.32074\/1591-951X-1603_ref19","doi-asserted-by":"crossref","unstructured":"Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024;391(17):1584-96.","DOI":"10.1056\/NEJMoa2404625"},{"key":"10.32074\/1591-951X-1603_ref20","doi-asserted-by":"crossref","unstructured":"Turner Nicholas C, Oliveira M, Howell Sacha J, Dalenc F, Cortes J, Gomez Moreno Henry L, et al. Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer. New England Journal of Medicine. 2023;388(22):2058-70.","DOI":"10.1056\/NEJMoa2214131"},{"key":"10.32074\/1591-951X-1603_ref21","doi-asserted-by":"crossref","unstructured":"Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, et al. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA\/AKT1\/PTEN Alterations. J Clin Oncol. 2024;42(34):4103-13.","DOI":"10.1200\/JCO.24.00427"},{"key":"10.32074\/1591-951X-1603_ref22","doi-asserted-by":"crossref","unstructured":"Schagerholm C, Robertson S, Toosi H, Sifakis EG, Hartman J. PIK3CA mutations in endocrine-resistant breast cancer. Scientific Reports. 2024;14(1):12542.","DOI":"10.1038\/s41598-024-62664-1"},{"key":"10.32074\/1591-951X-1603_ref23","doi-asserted-by":"crossref","unstructured":"Pepe F, Venetis K, Cursano G, Frascarelli C, Pisapia P, Vacirca D, et al. PIK3CA testing in hormone receptor-positive\/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories. Pharmacogenomics. 2024;25(3):161-9.","DOI":"10.2217\/pgs-2023-0238"},{"key":"10.32074\/1591-951X-1603_ref24","doi-asserted-by":"crossref","unstructured":"Hossain MT, Hossain MA. Targeting PI3K in Cancer Treatment: A Comprehensive Review with Insights from Clinical Outcomes. Eur J Pharmacol. 2025:177432.","DOI":"10.1016\/j.ejphar.2025.177432"},{"key":"10.32074\/1591-951X-1603_ref25","doi-asserted-by":"crossref","unstructured":"Asnaghi R, Antonarelli G, Battaiotto E, Castellano G, Guidi L, Izzo D, et al. An update on promising and emerging protein kinase B\/AKT inhibitors for breast cancer. Expert Opin Pharmacother. 2025;26(3):235-47.","DOI":"10.1080\/14656566.2025.2454290"},{"key":"10.32074\/1591-951X-1603_ref26","doi-asserted-by":"crossref","unstructured":"Fusco N, Malapelle U, Rolfo C. Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration. Crit Rev Oncol Hematol. 2025:104619.","DOI":"10.1016\/j.critrevonc.2025.104619"},{"key":"10.32074\/1591-951X-1603_ref27","doi-asserted-by":"crossref","unstructured":"Pepe F, Russo G, Venetis K, Scimone C, Palumbo L, Nacchio M, et al. Harmonization trial on ESR1 testing strategies in ER+\/HER2- breast cancer patients: an Italian experience. J Liq Biopsy. 2025;9:100314.","DOI":"10.1016\/j.jlb.2025.100314"},{"key":"10.32074\/1591-951X-1603_ref28","doi-asserted-by":"crossref","unstructured":"Vigliar E, Iaccarino A, Sciortino M, De Luca C, Malapelle U, Bellevicine C, et al. Molecular predictive testing in precision oncology: The Italian experience. Cancer Cytopathol. 2020;128(9):622-8.","DOI":"10.1002\/cncy.22290"},{"key":"10.32074\/1591-951X-1603_ref29","doi-asserted-by":"crossref","unstructured":"Fusco N, Jantus-Lewintre E, Serrano MJ, Gandara D, Malapelle U, Rolfo C. Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration. Critical Reviews in Oncology\/Hematology. 2025:104619.","DOI":"10.1016\/j.critrevonc.2025.104619"},{"key":"10.32074\/1591-951X-1603_ref30","doi-asserted-by":"crossref","unstructured":"Buchta C, Marrington R, De la Salle B, Albarede S, Badrick T, Bietenbeck A, et al. Behind the scenes of EQA - characteristics, capabilities, benefits and assets of external quality assessment (EQA). Clin Chem Lab Med. 2025.","DOI":"10.2139\/ssrn.4957142"},{"key":"10.32074\/1591-951X-1603_ref31","doi-asserted-by":"crossref","unstructured":"Linko S, Boursier G, Bernabeu-Andreu FA, Dzneladze N, Vanstapel F, Brguljan PM, et al. EN ISO 15189 revision: EFLM Committee Accreditation and ISO\/CEN standards (C: A\/ISO) analysis and general remarks on the changes. Clin Chem Lab Med. 2025.","DOI":"10.1515\/cclm-2024-1451"},{"key":"10.32074\/1591-951X-1603_ref32","doi-asserted-by":"crossref","unstructured":"Dufraing K, Fenizia F, Torlakovic E, Wolstenholme N, Deans ZC, Rouleau E, et al. Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. Virchows Arch. 2021;478(3):553-65.","DOI":"10.1007\/s00428-020-02928-z"},{"key":"10.32074\/1591-951X-1603_ref33","doi-asserted-by":"crossref","unstructured":"van Krieken JH, Siebers AG, Normanno N. European consensus conference for external quality assessment in molecular pathology. Ann Oncol. 2013;24(8):1958-63.","DOI":"10.1093\/annonc\/mdt153"},{"key":"10.32074\/1591-951X-1603_ref34","doi-asserted-by":"crossref","unstructured":"Schneider F, Maurer C, Friedberg RC. International Organization for Standardization (ISO) 15189. Ann Lab Med. 2017;37(5):365-70.","DOI":"10.3343\/alm.2017.37.5.365"},{"key":"10.32074\/1591-951X-1603_ref35","doi-asserted-by":"crossref","unstructured":"McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, et al. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. Eur J Hum Genet. 2024;32(5):479-88.","DOI":"10.1038\/s41431-023-01507-5"},{"key":"10.32074\/1591-951X-1603_ref36","doi-asserted-by":"crossref","unstructured":"Park L, Thompson SL, Roose J, Lu Y, Chaki M, Lam C, et al. Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+\/HER2- metastatic breast cancer (mBC) in the US. Journal of Clinical Oncology. 2024;42(16_suppl):1041-.","DOI":"10.1200\/JCO.2024.42.16_suppl.1041"},{"key":"10.32074\/1591-951X-1603_ref37","doi-asserted-by":"crossref","unstructured":"Vollbrecht C, Hoffmann I, Lehmann A, Merkelbach-Bruse S, Fassunke J, Wagener-Ryczek S, et al. Proficiency testing of PIK3CA mutations in HR+\/HER2-breast cancer on liquid biopsy and tissue. Virchows Arch. 2023;482(4):697-706.","DOI":"10.1007\/s00428-022-03445-x"},{"key":"10.32074\/1591-951X-1603_ref38","doi-asserted-by":"crossref","unstructured":"Suppan C, Graf R, Jahn S, Zhou Q, Klocker EV, Bartsch R, et al. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. Br J Cancer. 2022;126(3):456-63.","DOI":"10.1038\/s41416-021-01601-9"},{"key":"10.32074\/1591-951X-1603_ref39","doi-asserted-by":"crossref","unstructured":"Kim E, Dhillon PK, Lambert P, Cheng A, Basho RK. PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice. Journal of Clinical Oncology. 2024;42(16_suppl):e13059-e.","DOI":"10.1200\/JCO.2024.42.16_suppl.e13059"},{"key":"10.32074\/1591-951X-1603_ref40","doi-asserted-by":"crossref","unstructured":"Bravaccini S, Mazza M, Maltoni R. No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country. Breast Cancer Res Treat. 201. Netherlands: \u00a9 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.; 2023. p. 1-3.","DOI":"10.1007\/s10549-023-07000-3"},{"key":"10.32074\/1591-951X-1603_ref41","doi-asserted-by":"crossref","unstructured":"Giorgi Rossi P, Djuric O, Navarra S, Rossi A, Di Napoli A, Frova L, et al. Geographic Inequalities in Breast Cancer in Italy: Trend Analysis of Mortality and Risk Factors. Int J Environ Res Public Health. 2020;17(11).","DOI":"10.3390\/ijerph17114165"},{"key":"10.32074\/1591-951X-1603_ref42","doi-asserted-by":"crossref","unstructured":"Ferraris G, Coppini V, Ferrari MV, Monzani D, Grasso R, Pravettoni G. Understanding Reasons for Cancer Disparities in Italy: A Qualitative Study of Barriers and Needs of Cancer Patients and Healthcare Providers. Cancer Control. 2024;31:10732748241258589.","DOI":"10.1177\/10732748241258589"},{"key":"10.32074\/1591-951X-1603_ref43","doi-asserted-by":"crossref","unstructured":"Ma A, O\u2019Shea R, Wedd L, Wong C, Jamieson RV, Rankin N. What is the power of a genomic multidisciplinary team approach? A systematic review of implementation and sustainability. Eur J Hum Genet. 2024;32(4):381-91.","DOI":"10.1038\/s41431-024-01555-5"},{"key":"10.32074\/1591-951X-1603_ref44","doi-asserted-by":"crossref","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23.","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"10.32074\/1591-951X-1603_ref45","doi-asserted-by":"crossref","unstructured":"Fusco N, Pruneri G, Pagni F, Malapelle U. Molecular Testing in Solid Tumors: Best Practices from the Molecular Pathology and Precision Medicine Study Group of the Italian Society of Pathology (PMMP\/SIAPeC): Shaping Excellence in Molecular Diagnostics. Pathologica-Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology. 2025;117.","DOI":"10.32074\/1591-951X-1214"},{"key":"10.32074\/1591-951X-1603_ref46","doi-asserted-by":"crossref","unstructured":"Marchi\u00f2 C, Berrino E, Scarpino S, Al\u00ec G, Bellomo SE, Buglioni S, et al. Part I\u2013Pre-analytical phase. Pathologica-Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology. 2025;117.","DOI":"10.32074\/1591-951X-1215"},{"key":"10.32074\/1591-951X-1603_ref47","doi-asserted-by":"crossref","unstructured":"Guerini-Rocco E, Venetis K, Bessi S, Buglioni S, Chiappetta C, de Biase D, et al. Part II\u2013Analytical phase. Pathologica-Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology. 2025;117.","DOI":"10.32074\/1591-951X-1216"},{"key":"10.32074\/1591-951X-1603_ref48","doi-asserted-by":"crossref","unstructured":"Buglioni S, Seminati D, Bruno R, Casini B, Gristina V, Guerini-Rocco E, et al. Part III\u2013Post-analytical phase. Pathologica-Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology. 2025;117.","DOI":"10.32074\/1591-951X-1217"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:32:50Z","timestamp":1775737970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1603","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"4"}}